Kisqali

News

ESMO: Lilly reveals scale of survival win with Verzenio

Eli Lilly has revealed long-term follow-up data with adjuvant Verzenio in early breast cancer, including a 15.8% improvement in survival.

News

Packets of Verzenio fanned out on display

Lilly raises stakes in Novartis battle with Verzenio data

Armed with new survival data for Verzenio in early breast cancer, Lilly hopes to keep the drug's nose in front of a fast-growing rival from Novartis.

News

NICE relents and backs Kisqali for wide use in breast cancer

Novartis' breast cancer therapy Kisqali has been cleared for NHS use in early breast cancer, an indication driving blockbuster sales of the drug.

News

Kisqali gets early breast cancer approval in Europe

Novartis' fast-growing breast cancer drug gets another growth driver as EU approves adjuvant use in patients with early-stage HR+, HER2- tumours

News

Lilly on alert as new Kisqali approval threatens Verzenio

Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over class rival Verzenio from Eli Lilly.

News

ASCO: Novartis touts Kisqali adjuvant breast cancer data

Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte

ESMO: Lilly reveals scale of survival win with Verzenio

Lilly raises stakes in Novartis battle with Verzenio data

NICE relents and backs Kisqali for wide use in breast cancer

Kisqali gets early breast cancer approval in Europe

Lilly on alert as new Kisqali approval threatens Verzenio

ASCO: Novartis touts Kisqali adjuvant breast cancer data

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Kisqali

Editor's Picks